OncoMatch/Clinical Trials/NCT06882057
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Is NCT06882057 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Blinatumomab and Reinduction-2 omission for acute lymphoblastic leukemia all.
Treatment: Blinatumomab · Reinduction-2 omission · Chemo-light Maintenance 2 — CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy in all newly diagnosed provisional low-risk (LR) pediatric acute lymphoblastic leukemia (ALL) patients, regardless of measurable residual diseases (MRD) status. We will compare the efficacy of chemotherapy combined with Blina-14, comparing to CAT+ intensification or historical regimens. Patients with early remission in depth will receive chemo-light late intensification and maintenance therapy afterwards. Early complete remission in depth and maintenance reduction will be determined by next-generation sequencing (Ig-NGS MRD).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Philadelphia chromosome positive ALL (Ph-ALL)
Excluded: IGHM surface IgM positive
sIgM+
Disease stage
Required: Stage LOW RISK GROUP
Excluded: Stage I/HR B-ALL GROUP
Low risk group; I/HR B-ALL group [excluded]
Demographics
Prior therapy
Cannot have received: glucocorticoid
Glucocorticoid treatment for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06882057 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with ABL1 alterations eligible?
No. ABL1 fusion is an exclusion criterion.
Are patients with IGHM alterations eligible?
No. IGHM surface IgM positive is an exclusion criterion.
What disease stage is eligible?
Stage LOW RISK GROUP is required.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages